Clinical Trial Update: A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 dose-finding and efficacy study of a triplet therapy (venetoclax, CC-486, and obinutuzumab) in follicular lymphoma has completed, with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• CC-486 (azacitidine)
• Obinutuzumab (obinutuzumab)
• Venetoclax (venetoclax)

Snippet

Sponsor: University of Chicago | Conditions: Follicular Lymphoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2024-05-16